Review Article
No access
Published Online: 10 October 2014

Non-Thyroidal Illness in the ICU: A Syndrome with Different Faces

Publication: Thyroid
Volume 24, Issue Number 10

Abstract

Background: Critically ill patients typically present with low or low-normal plasma thyroxine, low plasma triiodothyronine (T3), increased plasma reverse T3 (rT3) concentrations, in the absence of a rise in thyrotropin (TSH). This constellation is referred to as nonthyroidal illness syndrome (NTI). Although it is long known that the severity of NTI is associated with risk of poor outcomes of critical illness, the causality in this association has not been well investigated.
Summary: In this narrative review, the different faces of NTI during critical illness are highlighted. Acute alterations are dominated by changes in thyroid hormone binding, peripheral thyroid hormone uptake, and alterations in the expression and activity of the type-1 and type-3 deiodinases. It was recently shown that at least part of these acute changes are brought about by concomitant macronutrient restriction, and this part appears adaptive and beneficial. However, the face of the NTI in the prolonged phase of critical illness is different, when patients are fully fed but continue to depend on intensive medical care. In that prolonged phase of illness, hypothalamic thyrotropin releasing hormone (TRH) expression is suppressed and explains reduced TSH secretion and whereby reduced thyroidal hormone release. During prolonged critical illness, and in the presence of adequate nutrition, several tissue responses could be interpreted as compensatory to low thyroid hormone availability, such as increased expression of monocarboxylate transporters, upregulation of type-2 deiodinase activity, and increased sensitivity at the receptor level. Infusing hypothalamic releasing factors in these prolonged critically ill patients can reactivate the thyroid axis and induce an anabolic response.
Conclusions: It is clear that the name “NTI” during critical illness refers to a syndrome with different faces. Tolerating the early “fasting response” to critical illness and its concomitant changes in thyroid hormone parameters appears to be wise and beneficial. This thus applies to the NTI present in the majority of the patients treated in intensive care units. However, the NTI that occurs in prolonged critically ill patients appears different with regard to both its causes and consequences. Future studies should specifically target this selected population of prolonged critically ill patients, and, after excluding iatrogic drug interferences, investigate the effect on outcome of treatment with hypothalamic releasing factors in adequately powered randomized controlled trials.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Utiger RD 1980 Decreased extrathyroidal triiodothyronine production in nonthyroidal illness: benefit or harm? Am J Med 69:807–810.
2.
Wartofsky L, Burman KD 1982 Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome.” Endocr Rev 3:164–217.
3.
Van den Berghe G, de Zegher F, Bouillon R 1998 Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83:1827–1834.
4.
Boelen A, Kwakkel J, Fliers E 2011 Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev 32:670–693.
5.
Boonen E, Van den Berghe G 2014 Endocrine responses to critical illness: novel insights and therapeutic implications. J Clin Endocrinol Metab 99:1569–1582.
6.
Boelen A, Wiersinga WM, Fliers E 2008 Fasting-induced changes in the hypothalamus-pituitary-thyroid axis. Thyroid 18:123–129.
7.
Everts ME, de Jong M, Lim CF, Docter R, Krenning EP, Visser TJ, Hennemann G 1996 Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Thyroid 6:359–368.
8.
Gardner DF, Kaplan MM, Stanley CA, Utiger RD 1979 Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 300:579–584.
9.
Boelen A, van Beeren M, Vos X, Surovtseva O, Belegri E, Saaltink DJ, Vreugdenhil E, Kalsbeek A, Kwakkel J, Fliers E 2012 Leptin administration restores the fasting-induced increase of hepatic type 3 deiodinase expression in mice. Thyroid 22:192–199.
10.
De Groot LJ 1999 Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151–164.
11.
Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G 2005 Serum rT3 and T3/rT3 are prognostic markers in critically ill patients and are associated with post-mortem tissue deiodinase activities. J Clin Endocrinol Metab 90:4559–4565.
12.
Bello G, Pennisi MA, Montini L, Silva S, Maviglia R, Cavallaro F, Bianchi A, De Marinis L, Antonelli M 2009 Nonthyroidal illness syndrome and prolonged mechanical ventilation in patients admitted to the ICU. Chest 135:1448–1454.
13.
Becker RA, Vaughan GM, Ziegler MG, Seraile LG, Goldfarb IW, Mansour EH, McManus WF, Pruitt BA Jr, Mason AD Jr 1982 Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med 10:870–875.
14.
Sirlak M, Yazicioglu L, Inan MB, Eryilmaz S, Tasoz R, Aral A, Ozyurda U 2004 Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg 26:720–725.
15.
Brent GA, Hershman JM 1986 Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 63:1–8.
16.
Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP 2000 A trial of thyroxine in acute renal failure. Kidney Int 57:293–298.
17.
Docter R, van Toor H, Krenning EP, de Jong M, Hennemann G 1993 Free thyroxine assessed with three assays in sera of patients with nonthyroidal illness and of subjects with abnormal concentrations of thyroxine-binding proteins. Clin Chem 39:1668–1674.
18.
Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G 2003 Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88:3202–3211.
19.
Rodriguez-Perez A, Palos-Paz F, Kaptein E, Visser TJ, Dominguez-Gerpe L, Alvarez-Escudero J, Lado-Abeal J 2008 Identification of molecular mechanisms related to nonthyroidal illness syndrome in skeletal muscle and adipose tissue from patients with septic shock. Clin Endocrinol (Oxf ) 68:821–827.
20.
Michalaki M, Vagenakis AG, Makri M, Kalfarentzos F, Kyriazopoulou V 2001 Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 86:4198–4205.
21.
Romijn JA, Wiersinga WM 1990 Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 70:35–42.
22.
Persani L, Terzolo M, Asteria C, Orlandi F, Angeli A, Beck-Peccoz P 1995 Circadian variations of thyrotropin bioactivity in normal subjects and patients with primary hypothyroidism. J Clin Endocrinol Metab 80:2722–2728.
23.
Schlienger JL, Sapin R, Capgras T, Gasser F, Monassier JP, Hauer B, Arnold P 1991 [Evaluation of thyroid function after myocardial infarction]. Ann Endocrinol (Paris) 52:283–288.
24.
Rothwell PM, Udwadia ZF, Lawler PG 1993 Thyrotropin concentration predicts outcome in critical illness. Anaesthesia 48:373–376.
25.
Rothwell PM, Lawler PG 1995 Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 23:78–83.
26.
Ray DC, Macduff A, Drummond GB, Wilkinson E, Adams B, Beckett GJ 2002 Endocrine measurements in survivors and non-survivors from critical illness. Intensive Care Med 28:1301–1308.
27.
Redout EM, van der Toorn A, Zuidwijk MJ, van de Kolk CW, van Echteld CJ, Musters RJ, van Hardeveld C, Paulus WJ, Simonides WS 2010 Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 298:H1038–H1047.
28.
Wajner SM, Goemann IM, Bueno AL, Larsen PR, Maia AL 2011 IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. J Clin Invest 121:1834–1845.
29.
van der Poll T, Van Zee KJ, Endert E, Coyle SM, Stiles DM, Pribble JP, Catalano MA, Moldawer LL, Lowry SF 1995 Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 80:1341–1346.
30.
Lim CF, Docter R, Visser TJ, Krenning EP, Bernard B, van Toor H, de Jong M, Hennemann G 1993 Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab 76:1165–1172.
31.
Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K 1995 Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333:1522–1527.
32.
Mullis-Jansson SL, Argenziano M, Corwin S, Homma S, Weinberg AD, Williams M, Rose EA, Smith CR 1999 A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 117:1128–1134.
33.
Moshang T Jr, Parks JS, Baker L, Vaidya V, Utiger RD, Bongiovanni AM, Snyder PJ 1975 Low serum triiodothyronine in patients with anorexia nervosa. J Clin Endocrinol Metab 40:470–473.
34.
Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G 2011 Early versus late parenteral nutrition in critically ill adults. N Engl J Med 365:506–517.
35.
Casaer MP, Wilmer A, Hermans G, Wouters PJ, Mesotten D, Van den Berghe G 2013 Role of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. Am J Respir Crit Care Med 187:247–255.
36.
Hermans G, Casaer MP, Clerckx B, Güiza F, Vanhullebusch T, Derde S, Meersseman P, Derese I, Mesotten D, Wouters PJ, Van Cromphaut S, Debaveye S, Gosselink R, Gunst J, Wilmer A, Van den Berghe G, Vanhorebeek I 2013 Impact of tolerating macronutrient deficit on the development of intensive care unit-acquired weakness. Lancet Resp Med 1:621–629.
37.
Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, Claes K, Schetz M, Van den Berghe G 2013 Impact of early parenteral nutrition on metabolism and kidney injury. J Am Soc Nephrol 24:995–1005.
38.
Langouche L, Vander Perre S, Marques M, Boelen A, Wouters PJ, Casaer MP, Van den Berghe G 2013 Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab 98:1006–1013.
39.
Mebis L, Eerdekens A, Güiza F, Princen L, Derde S, Vanwijngaerden YM, Vanhorebeek I, Darras VM, Van den Berghe G, Langouche L 2012 Contribution of nutritional deficit to the pathogenesis of the nonthyroidal illness syndrome in critical illness: a rabbit model study. Endocrinology 153:973–984.
40.
Boelen A, Boorsma J, Kwakkel J, Wieland CW, Renckens R, Visser TJ, Fliers E, Wiersinga WM 2008 Type 3 deiodinase is highly expressed in infiltrating neutrophilic granulocytes in response to acute bacterial infection. Thyroid 18:1095–1103.
41.
Van den Berghe G, de Zegher F., Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY 1997 Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf ) 47:599–612.
42.
Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF 1997 Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 82:4032–4036.
43.
Bacci V, Schussler GC, Kaplan TB 1982 The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab 54:1229–1235.
44.
Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P 1989 Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975–978.
45.
Faglia G, Ferrari C, Beck-Peccoz P, Spada A, Travaglini P, Ambrosi B 1973 Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal subjects. Horm Metab Res 5:289–292.
46.
Van den Berghe G, de Zegher F, Lauwers P 1994 Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf ) 41:731–737.
47.
Van den Berghe G, de Zegher F, Lauwers P 1994 Dopamine suppresses pituitary function in infants and children. Crit Care Med 22:1747–1753.
48.
Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM 2004 Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol 182:315–323.
49.
Mebis L, Debaveye Y, Ellger B, Derde S, Ververs EJ, Langouche L, Darras VM, Fliers E, Visser TJ, Van den Berghe G 2009 Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness. Crit Care 13:R147.
50.
Alkemade A, Friesema EC, Kuiper GG, Wiersinga WM, Swaab DF, Visser TJ, Fliers E 2006 Novel neuroanatomical pathways for thyroid hormone action in the human anterior pituitary. Eur J Endocrinol 154:491–500.
51.
Langouche L, Princen L, Gunst J, Guiza F, Derde S, Van den Berghe G 2013 Anterior pituitary morphology and hormone production during sustained critical illness in a rabbit model. Horm Metab Res 45:277–282.
52.
Mebis L, Paletta D, Debaveye Y, Ellger B, Langouche L, D'Hoore A, Darras VM, Visser TJ, Van den Berghe G 2009 Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol 161:243–250.
53.
Mebis L, Langouche L, Visser TJ, Van den Berghe G 2007 The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab 92:3330–3333.
54.
Ma SF, Xie L, Pino-Yanes M, Sammani S, Wade MS, Letsiou E, Siegler J, Wang T, Infusino G, Kittles RA, Flores C, Zhou T, Prabhakar BS, Moreno-Vinasco L, Villar J, Jacobson JR, Dudek SM, Garcia JG 2011 Type 2 deiodinase and host responses of sepsis and acute lung injury. Am J Respir Cell Mol Biol 45:1203–1211.
55.
Thijssen-Timmer DC, Peeters RP, Wouters P, Weekers F, Visser TJ, Fliers E, Wiersinga WM, Bakker O, Van den Berghe G 2007 Thyroid hormone receptor isoform expression in livers of critically ill patients. Thyroid 17:105–112.
56.
Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY 1998 Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83:309–319.
57.
Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R 1999 Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84:1311–1323.
58.
Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R 2002 The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf ) 56:655–669.
59.
Weekers F, Michalaki M, Coopmans W, Van HE, Veldhuis JD, Darras VM, Van den Berghe G 2004 Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 145:205–213.
60.
Haugen BR 2009 Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 23:793–800.
61.
Van den Berghe G, de Zegher F, Lauwers P 1994 Dopamine suppresses pituitary function in infants and children. Crit Care Med 22:1747–1753.
62.
Bettendorf M, Schmidt KG, Grulich-Henn J, Ulmer HE, Heinrich UE 2000 Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study. Lancet 356:529–534.
63.
Debaveye Y, Ellger B, Mebis L, Van Herck E, Coopmans W, Darras V, Van den Berghe G 2005 Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology 146:5604–5611.
64.
Debaveye Y, Ellger B, Mebis L, Darras VM, Van den Berghe G 2008 Regulation of tissue iodothyronine deiodinase activity in a model of prolonged critical illness. Thyroid 18:551–560.
65.
Debaveye Y, Ellger B, Mebis L, Visser TJ, Darras VM, Van den Berghe G 2008 Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits. Endocrinology 149:4218–4228.

Information & Authors

Information

Published In

cover image Thyroid®
Thyroid
Volume 24Issue Number 10October 2014
Pages: 1456 - 1465
PubMed: 24845024

History

Published online: 10 October 2014
Published in print: October 2014
Published ahead of print: 19 June 2014
Published ahead of production: 20 May 2014

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Greet Van den Berghe
Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Notes

Address correspondence to:Greet Van den Berghe, MD, PhDClinical Division and Laboratory of Intensive Care MedicineKU LeuvenHerestraat 49B-3000 LeuvenBelgium
E-mail: [email protected]

Author Disclosure Statement

The author has no conflict of interest to declare.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top